Abbvie joins obesity race with Gubra amylin deal

Abbvie has become the latest big pharma to enter the obesity race, via a $350 million deal to license a clinical amylin program. The parameters of the partnership suggest that Abbvie either believes in the potential of amylin monotherapy or is not yet done adding to its obesity portfolio.

Abbvie Inc. (NYSE:ABBV) announced on Monday that it licensed exclusive, global rights to amylin agonist GUB014295 (formerly GUBamy) from Danish biotech Gubra A/S (CSE:GUBRA) for $350 million up front and up to nearly $1.9 billion in milestones, plus tiered royalties. ...